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343Abstracts
only depends on the clinical effectiveness of medications, but also
on how satisﬁed patients are with treatment information and
how well their treatment expectations are managed.
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OBJECTIVES: The presence of psychological distress, such as
depression and negative mood is very common in patients with
rheumatoid arthritis (RA). The purpose of this study was to
examine the impact of depression on RA patients’ quality of life.
METHODS: The study consisted of 1130 rheumatoid arthritic
patients from a Western US managed care organization. Longi-
tudinal data on diagnosis and quality of life was collected at
three annual periods. Patients’ health related quality of life was
measured by the Physical Component Summary (PCS) score
from the SF-36 as rheumatoid arthritis is generally considered a
disease with physical impairment. We derived the effect size in
order to compare the quality of life between the depressed 
and the non-depressed RA patients. A dynamic panel data model
was further developed to examine the impact of depression on
patients’ quality of life. The model contained the lagged depen-
dent variable (quality of life of the previous year). Other covari-
ates included in the model were demographic variables and
disease severity, as measured by Chronic Disease Score (CDS).
RESULTS: The incidence of depression in RA patients increased
from 10.18% to 14.42% over the study period. The effect size
of PCS fell into the medium category (0.5–0.8). The effect size
increased with time, indicating that the difference of quality of
life between the depressed and non-depressed RA patients
increases with the disease duration. Regression analysis from the
Panel data model revealed that depression had signiﬁcant effect
on RA patients’ quality of life after controlling for demographic
variables and disease severity (P < 0.01). CONCLUSIONS:
Depression in patients with rheumatoid arthritis can signiﬁcantly
affect their perceived quality of life. This result suggested that
patient intervention related to change patients’ coping style, or
illness conceptions should be encouraged.
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METHOTREXATE DEMONSTRATES SUSTAINED
IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES OVER
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OBJECTIVES: Abatacept (CTLA4Ig) is the ﬁrst in a new class
of agents for the treatment of RA that selectively modulates 
the co-stimulatory signal required for full T-cell activation, 
has shown good and efﬁcacy and tolerability during in a one-
year, double-blind, placebo-controlled trial of Abatacept in
methotrexate (MTX) inadequate responders. This analysis
examined the long-term effect of Abatacept on patient-reported
outcomes (PRO) in an open-label extension of this study at two-
years. METHODS: In the blinded phase of the study, patients
with active RA despite MTX treatment were randomized to
receive Abatacept 10mg/kg IV monthly + MTX or placebo +
MTX for one-year. Patients who completed the blinded phase
were eligible to enroll in the long-term extension during which
patients were treated with a ﬁxed dose of Abatacept 10mg/kg.
Patients evaluated pain and disease activity using the Visual
Analog Scale (VAS), physical function using the modiﬁed Health
Assessment Questionnaire (mHAQ), and QOL using the SF-36.
RESULTS: In total, 115 patients were randomized to the 
Abatacept + MTX group; 84 patients (73%) entered the LTE and
75 (89%) of these patients completed two-years of treatment.
Statistically signiﬁcant improvements from baseline in pain,
disease activity, and physical function were reported by 
Abatacept-treated patients as early as day 15, and were further
improved and maintained during two-years of treatment. The
improvements in patient reported outcomes preceded the
improvement seen in the overall clinical response measured by
the American College of Rheumatology criterion for a 50%
improvement. Abatacept also sustained signiﬁcant improvements
in all eight domains of the SF-36, with the greatest improvements
seen in physical function, role-physical, bodily pain, vitality and
social function domains. CONCLUSIONS: Abatacept rapidly
and signiﬁcantly improves patient-reported outcomes and these
improvements are sustained during two-years of treatment.
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OBJECTIVES: To conduct a meta-analysis on the diagnostic
accuracy of ﬁve screening tests for colorectal cancer (CRC):
faecal occult blood test (FOBT), double-contrast barium 
enema (DCBE), ﬂexible sigmoidoscopy (FSIG), conventional
colonoscopy (COL) and computed tomography colonoscopy
(CTCOL). METHODS: A literature search was carried out 
in MEDLINE (1966–2004) for each of the ﬁve tests. Articles
were reviewed by two independent reviewers according to the
Berkeley Systematic Reviews guidelines. Inclusion criteria were:
1) RCTs or observational studies of screening methods for CRC;
2) subjects patients with low to average risk of colorectal cancer;
and 3) complete data to calculate sensitivity and speciﬁcity.
Exclusion criteria were: 1) non-peer reviewed articles; 2) any
articles whose primary aim was not to assess colorectal cancer
screening; 3) articles not in English or French; 4) articles pub-
lished prior to 1975; and 5) high risk screening populations. 
Heterogeneity within screening test groups was evaluated using
X2 test. Combining diagnostic accuracy measures, a summary
operator-receiver curve (SROC) was constructed with sensitivity
(from pooled data) and speciﬁcity (from SROC) for each CRC
screening test. RESULTS: Initial literature search found 399 for
FOBT, 253 for DCBE, 394 for FSIG, 434 for COL, and 345 for
CTCOL. Of these, 12, 8, 10, 8, and 13 articles respectively, were
selected for inclusion in the ﬁnal analysis. COL is the only screen-
ing strategy without signiﬁcant heterogeneity among studies (p
= 0.078). Sensitivity and speciﬁcity for FOBT, DCBE, FSIG, COL
and CTCOL was 0.543 and 0.976, 0.760 and 0.990, 0.749 and
0.9998, 0.866 and 0.999, 0.867 and 0.972, respectively. CON-
CLUSIONS: Speciﬁcity of all screening tests is high with greater
variation evident in the sensitivity (0.54–0.87) estimates. COL
results are considered most reliable. Additional studies are
required to validate CTCOL results due to signiﬁcant hetero-
geneity. Positive FOBT, DCBE, FSIG and CTCOL results must
be further investigated with COL.
